ClinPhone and invivodata create a new global partnership to provide electronic patient reported outcomes (ePRO) solutions.
Nottingham, UK, and Pittsburgh, PA- April 30, 2008-ClinPhone ( www.clinphone.com ), the world’s largest Clinical Technology Organization and invivodata ( www.invivodata.com ), the leading provider of device-based eDiaries, announced today an exclusive new global partnership to provide electronic patient reported outcomes (ePRO) solutions.
This new partnership will deliver best-of-breed offerings for the two most commonly used ePRO modalities-device-based and IVRS (Interactive Voice Response System) to pharmaceutical and biotech companies. As part of this collaboration, ClinPhone joins invivodata’s PROPartner™ Program, which enables invivodata customers to leverage the strengths of an impressive roster of affiliate technology and service companies whose offerings have been identified as “best-in-class” in their respective market areas.
The alliance between these two industry leaders brings customers a combination of support and expertise that surpasses anything currently offered in the marketplace in terms of helping them understand which modality would be best suited for their study.
ClinPhone and invivodata both focus heavily on regulatory and psychometric validation issues. In addition, both companies have strong relationships with industry thought leaders and instrument authors, furthering the value that this partnership will bring to customers.
Doug Engfer, founder, president, and chief executive officer of invivodata stated, “Successful use of ePRO today requires an in-depth understanding of scientific and regulatory considerations, coupled with appropriate technology and complete global support services. invivodata and ClinPhone have collaborated on and shared in many of the same efforts, organizations and events designed to promote sound ePRO research. This formal partnership strengthens this collaboration and delivers real value and best-of-breed solutions to our clients.”
Steve Kent, chief executive officer of ClinPhone, commented, “Usage of PRO and ePRO in clinical trials is increasing. By offering invivodata’s device-based ePRO options to our customers, we can expand our ability to meet their broader ePRO needs. This partnership also means we are able to provide sponsors with additional balanced and science-based guidance in line with evolving regulatory considerations.”
ClinPhone ePRO is renowned as an industry-leading IVR-based solution and offers an intuitive and easy-to-use solution for capturing patient self-reported data. This ranges from simple diaries to sophisticated health-related quality of life instruments. invivodata’s device-based ePRO solutions are based on over 20 years of experience, combining the scientific and regulatory expertise needed for ePRO with practical technology and proactive services to deliver accurate and reliable PRO data to clinical trial sponsors.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.